


Signant SmartSignals® Solutions for Melanoma

PATIENT SUPPORT MEETS RELIABLE DATA COLLECTION



Melanoma rates are increasing, particularly in young people. Its propensity to spread to other organs makes it the deadliest of all skin cancers. While advances in combination therapy are encouraging, there is still much work to be done. Signant's SmartSignals solutions can generate reliable evidence while improving the clinical trial experience for patients everywhere.

COLLECT ACCURATE DATA

Signant's eCOA solution features a library of pre-validated, disease-specific questionnaires. The digital platform collects real-time insights into the patients' symptoms, satisfaction with the treatment, as well as the treatment's effect on their quality of life. Unlike with paper-based methods, eCOA generates logical, attributable, and accurate data.

CONDUCT MULTI-PERSON MEETINGS

Signant's Telemedicine solution is a secure, virtual platform that enables multi-person meetings, allowing you to add specialists or caregivers. The digital tool can replace visits that do not require in-person evaluations with convenient, at-home meetings. The technology's screen-sharing capabilities even allow you to annotate on top of medical images to improve patient comprehension.

OPTIMIZE SUPPLY MANAGEMENT

Randomization & Trial Supply Management (RTSM) handles the multiple cohorts and combined medications involved in melanoma research with ease. Its proprietary algorithms intelligently direct the supplies only where they're needed.

GAIN RICHER INSIGHTS

Integrate our eCOA with Actigraph sensors and wearables to stream a continuous, real-time view of each patients' health status directly to the study teams. The objective data on sleep and activity patterns will enable enhanced insights into the post-treatment recovery.

SIMPLIFY CONSENT & RECONSENT

Choose any of our tiered eConsent solutions to help convey complex information about the disease and study to patients. The solution lets patients flag sections that require further clarification and checks their comprehension for a truly informed consent. It also manages the multiple consents common in oncology studies, ensuring the correct forms are always completed.

At Signant, our SmartSignals solution suite was designed specifically to meet the needs of sponsors, sites, and patients.

SIGNANT'S MELANOMA EXPERIENCE BY THE NUMBERS



I - IV
PHASES



21
TRIALS



1.6k
SITES



10.5k
PATIENTS



25
COUNTRIES



33
LANGUAGES

DRIVE BETTER RESEARCH OUTCOMES WITH SIGNANT SMARTSIGNALS SOLUTIONS

These solutions can be used individually or integrated together for a seamless, end-to-end digital experience.




eCOA

[LEARN MORE →](#)



eCONSENT

[LEARN MORE →](#)



RTSM

[LEARN MORE →](#)




ACTIVITY
MONITORING

[LEARN MORE →](#)

DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics



[MEET THE EXPERTS →](#)